Funds and ETFs OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
0.9253 USD -4.38% Intraday chart for OptiNose, Inc. -9.28% -28.27%

ETFs positioned on OptiNose, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.00% 34 M€ +2.35% -
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9253 USD
Average target price
3.75 USD
Spread / Average Target
+305.27%
Consensus
  1. Stock Market
  2. Equities
  3. OPTN Stock
  4. Funds and ETFs OptiNose, Inc.